How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis

• HOSHINO Junichi

  Nephrology Center, Toranomon Hospital

• UBARA Yoshifumi

  Nephrology Center, Toranomon Hospital

• SAWA Naoki

  Nephrology Center, Toranomon Hospital

• SUMIDA Keiichi

  Nephrology Center, Toranomon Hospital

• HIRAMATSU Rikako

  Nephrology Center, Toranomon Hospital

• HASEGAWA Eiko

  Nephrology Center, Toranomon Hospital

• SUWABE Tatsuya

  Nephrology Center, Toranomon Hospital

• HAYAMI Noriko

  Nephrology Center, Toranomon Hospital

• YAMANOUCHI Masayuki

  Nephrology Center, Toranomon Hospital

• TAKEMOTO Fumi

  Nephrology Center, Toranomon Hospital

• TANIGUCHI Shuichi

  Department of Hematology, Toranomon Hospital

• TAKAICHI Kenmei

  Nephrology Center, Toranomon Hospital

収録刊行物

• Clinical and experimental nephrology

  Clinical and experimental nephrology 15 (4), 486-492, 2011-08-01

キーワード

• Systemic AL amyloidosis
• Treatment
• Prognosis
• Melphalan
• VAD

詳細情報

• CRID: 1573950399749035392
• NII論文ID: 10029571663
• NII書誌ID: AA11126935
• ISSN: 13421751
• 本文言語コード: en
• データソース種別:
  • CiNii Articles